Scholarlink

<p>The EMBARK trial demonstrated improved survival with enzalutamide plus androgen deprivation therapy (ADT) in non-metastatic hormone-sensitive prostate cancer patients with high-risk biochemical recurrence (BCR), although staged using conventional imaging. Given the higher sensitivity of PSMA-PET, many of these patients could harbor metastatic disease. We retrospectively analyzed 587 patients with first BCR after radical treatment who underwent PSMA-PET. Patients were stratified according to EMBARK criteria for high-risk BCR. 169 patients (29%) met EMBARK criteria. They more often showed PSMA-PET positivity for any localization (82% vs 39%; <i>p</i> &lt; 0.001) and metastatic disease (46% vs 15%; <i>p</i> &lt; 0.001). Median PSA was higher and PSA doubling-time (PSADT) shorter (2.23 vs 0.43 ng/mL; 4.3 vs 9 months). Most High-risk BCR patients have a positive PSMA-PET, and many of these harbor metastatic disease at molecular imaging. Given the survival benefit from intensified systemic treatment with ARPI in this cohort, how to best combine systemic therapy with PSMA-PET guided metastases-directed-treatments remains an important future area of research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an “EMBARK-Like” cohort

  • 期刊论文

  • 发表日期：

    2026年2月25日

查看全文
  • Matteo Droghetti,
  • Valerio Pirelli,
  • Francesco Ceci,
  • Andrea Farolfi,
  • Matteo Bauckneht,
  • Francesco Lanfranchi,
  • Andrea Di Giorgio,
  • Paolo Castellucci,
  • Caterina Maria Paola Sgro,
  • Carlos Artigas,
  • Jose Leite,
  • Paola Corona,
  • Qaid Ahmed Shagera,
  • Renata Moreira,
  • Christian González,
  • Marcelo Queiroz,
  • Felipe de Galiza Barbosa,
  • Guido Rovera,
  • Desiree Deandreis,
  • Sara Tamburini,
  • Lorenzo Nanni,
  • Federico Bevilacqua,
  • Pietro Piazza,
  • Angelo Mottaran,
  • Veronica Mollica,
  • Francesco Massari,
  • Stefano Fanti,
  • Lorenzo Bianchi,
  • Riccardo Schiavina

摘要

The EMBARK trial demonstrated improved survival with enzalutamide plus androgen deprivation therapy (ADT) in non-metastatic hormone-sensitive prostate cancer patients with high-risk biochemical recurrence (BCR), although staged using conventional imaging. Given the higher sensitivity of PSMA-PET, many of these patients could harbor metastatic disease. We retrospectively analyzed 587 patients with first BCR after radical treatment who underwent PSMA-PET. Patients were stratified according to EMBARK criteria for high-risk BCR. 169 patients (29%) met EMBARK criteria. They more often showed PSMA-PET positivity for any localization (82% vs 39%; p < 0.001) and metastatic disease (46% vs 15%; p < 0.001). Median PSA was higher and PSA doubling-time (PSADT) shorter (2.23 vs 0.43 ng/mL; 4.3 vs 9 months). Most High-risk BCR patients have a positive PSMA-PET, and many of these harbor metastatic disease at molecular imaging. Given the survival benefit from intensified systemic treatment with ARPI in this cohort, how to best combine systemic therapy with PSMA-PET guided metastases-directed-treatments remains an important future area of research.